Navigation Links
Orexigen® Therapeutics Announces Multiple Contrave® Data Presentations at the 29th Annual Scientific Meeting of The Obesity Society
Date:9/29/2011

SAN DIEGO, Sept. 29, 2011 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX), today announced multiple Contrave® (naltrexone sustained release (SR)/bupropion SR) abstracts accepted for poster presentations and an oral presentation at the upcoming 29th Annual Scientific Meeting of The Obesity Society. This meeting will be held October 1-5, 2011 in Orlando, FL at the Orlando World Center Marriott.

Details on the presentation times are as follows:Monday, October 3, 2011 – Abstract #598-P, Presentation time 12:30-1:30PM EDT, Cypress BallroomPresenter: Robert Chilton, DO; University of Texas Health Science Center, San Antonio, TX, USA.Title: Naltrexone SR/Bupropion SR Combination Therapy Improves Predicted 10-Year Risk of Cardiovascular Disease, Coronary Heart Disease, Myocardial Infarction, and Congestive Heart FailureMonday, October 3, 2011 – Abstract #605-P, Presentation time 12:30-1:30PM EDT, Cypress BallroomPresenter: Ken Fujioka, MD; Scripps Clinic, La Jolla, CA, USA.Title: Completion of 56 Weeks of Naltrexone SR/Bupropion SR Combination Therapy Increases Likelihood of Achieving Improvements in Markers of Cardiometabolic Risk Associated with Clinically Meaningful Weight LossMonday, October 3, 2011 – Abstract #607-P, Presentation time 12:30-1:30PM EDT, Cypress BallroomPresenter: Patrick O'Neil, PhD; Medical University of South Carolina, Charleston, SC, USA.Title: Naltrexone SR/Bupropion SR and Intensive Behavioral Modification Combination Increases the Likelihood of Achieving Early and Sustained Weight Loss and Associated Improvement in Markers of Cardiometabolic RiskMonday, October 3, 2011 – Abstract #49-OR, Presentation time 3:15-4:45PM EDT, "Intervention and Clinical Studies - Surgery/Drugs" SessionPresenter: Gene-Jack Wang, MD; Brookhaven National Laboratory, Upton, NY Title: Reduced responses to food cue after combined therapy with naltrexone and bupropionAbout ContraveContrave, an investigational combination therapy of naltrexone HCl and bupropion HCl, was studied for its ability to help people with obesity initiate and sustain weight loss of at least 5 percent of their starting body weight in one year. Contrave was submitted for U.S. regulatory approval in March 2010. The original submission was based on multiple clinical trials that evaluated Contrave in more than 4500 patients. Orexigen received a Complete Response letter from FDA on January 31, 2011.

About Orexigen TherapeuticsOrexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. Contrave has completed Phase 3 clinical trials, and the Company's other product candidate, Empatic(TM), has completed Phase 2 clinical trials. Further information about the Company can be found at www.orexigen.com.


'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Orexigen® Therapeutics Presents Additional Contrave® Data from Phase 3 COR-II Trial on 24-Hour Ambulatory Blood Pressure Monitoring
2. Orexigen® Therapeutics Announces Upcoming Data Presentation at the American College of Cardiology Annual Scientific Meeting
3. Orexigen® Therapeutics Announces Corporate Realignment
4. Orexigen® Therapeutics to Present at JP Morgan Healthcare Conference
5. Orexigen® Therapeutics Schedules November 3, 2010 Webcast Discussion of Financial Results for the Third Quarter Ended September 30, 2010
6. Orexigen® Therapeutics Announces Upcoming Data Presentations at the 28th Annual Scientific Meeting of The Obesity Society
7. Halozyme Therapeutics to Present at the JMP Securities Healthcare Conference on September 28
8. ALS Therapy Development Institute and Aestus Therapeutics, Inc., Expand Collaboration on Development of Novel ALS Therapies
9. Healthpoint Biotherapeutics to Present at UBS Global Life Sciences Conference
10. PharmaVentures Engaged by Astex Therapeutics to Assist in the Divestment of US Facility
11. CMC Biologics Licenses Its CHEF1® Expression System to Oxford BioTherapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... ... February 04, 2016 , ... Shimadzu Scientific Instruments will ... live demos and poster sessions, and present on the analysis of mycotoxins and ... March 6 to 10 at the Georgia World Congress Center in Atlanta, Georgia. ...
(Date:2/4/2016)... PARK, Calif. , Feb. 4, 2016   DelMar ... biopharmaceutical company focused on the development and commercialization of new ... 18 th Annual BIO CEO & Investor Conference ... in New York, NY . ... an update on the ongoing clinical trial of VAL-083 ...
(Date:2/4/2016)... Sinovac Biotech Ltd. ("Sinovac" or the "Company") (NASDAQ: ... China , today announced that the ... February 4, 2016 a preliminary non-binding proposal letter, dated ... V-Ming ( Shanghai ) Investment Holdings Co., ... Shenzhen ) Fund Management Co., Ltd., Beijing ...
(Date:2/3/2016)... SAN DIEGO , Feb. 3, 2016 /PRNewswire/ ... medicine company with the first pluripotent stem cell-derived ... 1 diabetes in clinical-stage development, today announced that ... Janssen Pharmaceutical Companies of Johnson & Johnson, have ... BetaLogics group into ViaCyte.  The agreement provides ViaCyte ...
Breaking Biology Technology:
(Date:1/8/2016)... , January 8, 2016 NXTD ... and WorldVentures ® , a privately held leading direct ... Inc. 5000 fastest-growing company announced that on ... of $2 million in Nxt-ID to develop a proprietary ... Nxt-ID,s Wocket ® , a unique smart wallet that ...
(Date:1/7/2016)... 7, 2016 Various factors have contributed ... such as biologics and biosimilars. Some of these ... expenditure, growing demand for cost-effective alternatives, growing burden ... are similar versions of their corresponding patented biologic ... quality, safety, and efficacy. The global biosimilars market ...
(Date:1/6/2016)... 6, 2016  Varam Capital, a provider of micro-finance ... to deliver advanced authentication solutions to their clients. Varam ... poor. A loan of a few thousand rupees may ... the ability to purchase livestock or equipment for a ... stock for a local store. ...
Breaking Biology News(10 mins):